Abstract
Laboratory studies on clotrimazole showed that it had marked activity in vitro against all the Candida spp. and Cryptococcus spp. tested, against almost all strains of dermatophytes, and against Aspergillus spp and other fungal genera responsible for systemic mycoses; it had limited activity towards Gram-positive bacteria. The majority of Candida strains required MICs below 1 μg/ml and MCCs below 2 μg/ml.
Serum, urine, and faecal assays of clotrimazole were made by microbiological methods on five children who received 100 mg/kg/day clotrimazole for several weeks. In-vitro sensitivity tests and biological fluid drug assays are also reported on specimens from 18 patients in other hospitals receiving clotrimazole for severe candidosis; several were renal transplant cases. Similar investigations are reported on specimens from 18 patients with pulmonary aspergilloses.
The significance of low levels of the drug in body fluids, even after prolonged therapy, is discussed, and it is suggested that clotrimazole may be the first of a long series of imidazole derivatives with varying pharmacological and therapeutic properties.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- ANDRIOLE V. T., KRAVETZ H. M. The use of amphotericin B in man. JAMA. 1962 Apr 28;180:269–272. doi: 10.1001/jama.1962.03050170001001. [DOI] [PubMed] [Google Scholar]
- Brugmans J. P., Van Cutsem J. M., Thienpont D. C. Treatment of long-term tinea pedis with miconazole. Double-blind clinical evaluation. Arch Dermatol. 1970 Oct;102(4):428–432. [PubMed] [Google Scholar]
- Holt R. J., Newman R. L. Candida in the faeces of children receiving oral tetracycline and phenoxymethyl penicillin. J Clin Pathol. 1967 Jan;20(1):80–83. doi: 10.1136/jcp.20.1.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
- LIGHTBOWN J. W., SULITZEANU D. The assay of penicillin in blood-serum using Sarcina lutea. Bull World Health Organ. 1957;17(4-5):553–567. [PMC free article] [PubMed] [Google Scholar]
- Marget W., Adam D. Bay B 5097, a new orally applicable antifungal substance with broadspectrum activity. Preliminary clinical and laboratory experiences in children. Acta Paediatr Scand. 1971 May;60(3):341–345. doi: 10.1111/j.1651-2227.1971.tb06668.x. [DOI] [PubMed] [Google Scholar]
- Oberste-Lehn H., Baggesen I., Plempel M. Erste klinische Erfahrungen bei System-Mykosen mit einem neuen oralen Antimykotikum. Dtsch Med Wochenschr. 1969 Jun 27;94(26):1365–passim. doi: 10.1055/s-0028-1111224. [DOI] [PubMed] [Google Scholar]
- Plempel M., Bartmann K., Büchel K. H., Regel E. Experimentelle Befunde über ein neues, oral wirksames Antimykotikum mit breiten Wirkungsspektrum. Dtsch Med Wochenschr. 1969 Jun 27;94(26):1356–passim. doi: 10.1055/s-0028-1111223. [DOI] [PubMed] [Google Scholar]